CA3197659A1 - New indazole acetylene derivatives - Google Patents
New indazole acetylene derivativesInfo
- Publication number
- CA3197659A1 CA3197659A1 CA3197659A CA3197659A CA3197659A1 CA 3197659 A1 CA3197659 A1 CA 3197659A1 CA 3197659 A CA3197659 A CA 3197659A CA 3197659 A CA3197659 A CA 3197659A CA 3197659 A1 CA3197659 A1 CA 3197659A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- indazol
- imidazol
- thiazol
- acetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20210859 | 2020-12-01 | ||
| EP20210859.3 | 2020-12-01 | ||
| PCT/EP2021/083279 WO2022117477A1 (en) | 2020-12-01 | 2021-11-29 | New indazole acetylene derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3197659A1 true CA3197659A1 (en) | 2022-06-09 |
Family
ID=73654642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3197659A Pending CA3197659A1 (en) | 2020-12-01 | 2021-11-29 | New indazole acetylene derivatives |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240002390A1 (https=) |
| EP (1) | EP4255908A1 (https=) |
| JP (1) | JP7840327B2 (https=) |
| KR (1) | KR20230116799A (https=) |
| CN (1) | CN116490182A (https=) |
| AR (1) | AR124170A1 (https=) |
| AU (1) | AU2021393722A1 (https=) |
| CA (1) | CA3197659A1 (https=) |
| CL (1) | CL2023001440A1 (https=) |
| CO (1) | CO2023006912A2 (https=) |
| CR (1) | CR20230218A (https=) |
| IL (1) | IL303064A (https=) |
| MX (1) | MX2023006176A (https=) |
| PE (1) | PE20240099A1 (https=) |
| WO (1) | WO2022117477A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114008049B (zh) | 2019-06-21 | 2024-07-05 | 豪夫迈·罗氏有限公司 | 用于癌症治疗的egfr抑制剂 |
| JP7840324B2 (ja) | 2020-12-01 | 2026-04-03 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規インダゾール誘導体 |
| JP2025516543A (ja) * | 2022-05-13 | 2025-05-30 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のためのアロステリックおよびオルソステリックｅｇｆｒ阻害剤の組み合わせ |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2987914C (en) * | 2015-06-30 | 2022-09-13 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| TW201834651A (zh) * | 2016-12-22 | 2018-10-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
| WO2018220149A1 (en) * | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Compounds |
| SG11202011818YA (en) * | 2018-06-29 | 2020-12-30 | Hoffmann La Roche | Compounds |
| CN113993591A (zh) * | 2019-06-21 | 2022-01-28 | 豪夫迈·罗氏有限公司 | 新egfr抑制剂 |
-
2021
- 2021-11-29 PE PE2023001615A patent/PE20240099A1/es unknown
- 2021-11-29 WO PCT/EP2021/083279 patent/WO2022117477A1/en not_active Ceased
- 2021-11-29 AU AU2021393722A patent/AU2021393722A1/en active Pending
- 2021-11-29 KR KR1020237018340A patent/KR20230116799A/ko active Pending
- 2021-11-29 CN CN202180079840.XA patent/CN116490182A/zh active Pending
- 2021-11-29 MX MX2023006176A patent/MX2023006176A/es unknown
- 2021-11-29 US US18/255,083 patent/US20240002390A1/en active Pending
- 2021-11-29 AR ARP210103288A patent/AR124170A1/es not_active Application Discontinuation
- 2021-11-29 EP EP21816073.7A patent/EP4255908A1/en active Pending
- 2021-11-29 IL IL303064A patent/IL303064A/en unknown
- 2021-11-29 JP JP2023527318A patent/JP7840327B2/ja active Active
- 2021-11-29 CA CA3197659A patent/CA3197659A1/en active Pending
- 2021-11-29 CR CR20230218A patent/CR20230218A/es unknown
-
2023
- 2023-05-18 CL CL2023001440A patent/CL2023001440A1/es unknown
- 2023-05-26 CO CONC2023/0006912A patent/CO2023006912A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116490182A (zh) | 2023-07-25 |
| US20240002390A1 (en) | 2024-01-04 |
| JP7840327B2 (ja) | 2026-04-03 |
| PE20240099A1 (es) | 2024-01-18 |
| CR20230218A (es) | 2023-07-07 |
| EP4255908A1 (en) | 2023-10-11 |
| JP2023550902A (ja) | 2023-12-06 |
| WO2022117477A1 (en) | 2022-06-09 |
| TW202237611A (zh) | 2022-10-01 |
| AR124170A1 (es) | 2023-02-22 |
| CL2023001440A1 (es) | 2023-12-01 |
| CO2023006912A2 (es) | 2023-06-09 |
| MX2023006176A (es) | 2023-06-08 |
| AU2021393722A1 (en) | 2023-04-13 |
| KR20230116799A (ko) | 2023-08-04 |
| IL303064A (en) | 2023-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3986566B1 (en) | New egfr inhibitors | |
| CN102985417B (zh) | 作为jak1抑制剂的哌啶-4-基氮杂环丁烷衍生物 | |
| US12552801B2 (en) | Indazole derivatives | |
| WO2020002487A1 (en) | Compounds | |
| CA3197659A1 (en) | New indazole acetylene derivatives | |
| JP7798887B2 (ja) | 新規インダゾール誘導体 | |
| WO2023217923A1 (en) | New indazole derivatives | |
| WO2023209090A1 (en) | Bicyclic heteroaromatic compounds and their application in the treatment of cancer | |
| RU2853003C1 (ru) | Новые индазолацетиленовые производные | |
| WO2022194803A1 (en) | Antibacterial compounds | |
| TWI915460B (zh) | 新穎吲唑乙炔衍生物、製備其之方法、包含其之醫藥組合物及其用途 | |
| HK40094041A (zh) | 新的吲唑乙炔衍生物 | |
| HK40092553A (zh) | 新的吲唑衍生物 | |
| HK40115444A (zh) | 新的吲唑衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241025 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241025 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241025 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251022 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251022 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251127 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251127 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260127 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260127 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260127 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260128 |